US equities |
INTC $65.64 ▼-28.71% AMZN $240.38 ▼-1.40% MU $882.99 ▼-5.49% NVDA $205.60 ▼-3.77% GOOGL $282.19 ▼-0.58% SNDK $1,173.52 ▼-11.77% SPCX $137.71 ▼-4.29% AMD $510.94 ▼-9.79%
FinancialContent

AtriCure, Inc. - Common Stock (NQ:ATRC)

61.30 -1.17 (-1.88%)
Delayed Quote Updated: 11:39 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
AtriCure Releases 2023 ESG Report
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Reports Third Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in the Stifel 2023 Healthcare Conference
From AtriCure, Inc.
Via Business Wire
News headline image
What 7 Analyst Ratings Have To Say About AtriCure ↗
 
Via Benzinga
News headline image
Analyst Ratings for AtriCure ↗
 
Via Benzinga
News headline image
Earnings Outlook For AtriCure ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About AtriCure ↗
Within the last quarter, AtriCure (NASDAQ:ATRC) has observed the following analyst ratings: 
Via Benzinga
News headline image
AtriCure to Announce Third Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Reports Second Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate at Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Announce Second Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market ↗
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
News headline image
AtriCure Reports First Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Announce First Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From AtriCure, Inc.
Via Business Wire
News headline image
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday ↗
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
News headline image
AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Reports Third Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Announce Third Quarter 2022 Financial Results
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
From AtriCure, Inc.
Via Business Wire
News headline image
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AtriCure, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >